# Rocket Pharmaceuticals (RCKT.US)

Canonical: https://gigainvestors.com/s/RCKT

Analysis as of: 2026-10-16T07:31:28.662Z. Financial observations: FY2018–FY2026.

Listing currency: USD. Reporting currency: USD.

## Verdict

Not a wonderful business

Quality tests for Buy: not passed (profit record: fail; earnings resilience is evidence only). Published buy qualification: no.

Share price: $2.36 per share; close as of 2026-10-15.

## Checklist

### understandable: fail

- 0 revenue declines in the last 10 years (informational)

- more than 2 net loss years

- Financial history: 9 years

- Years with declining revenue: 0

- Years with a net loss: 9

Chart: Net income; fiscal year observations.

- FY2018: -$75M

- FY2019: -$83M

- FY2020: -$147M

- FY2021: -$169M

- FY2022: -$222M

- FY2023: -$246M

- FY2024: -$259M

- FY2025: -$223M

- LTM to Jun 2026: -$17M

### moat: fail

- Years with nonpositive invested capital use equity plus debt and leases; positive earnings with no positive capital are shown above 100%.

- ROIC median below threshold

- ROIC worst years below threshold (more than 1 bad year allowed)

- ROIC, median of available years: -218.3%

- ROIC, second-lowest year: -279.4%

- Years with nonpositive capital: 1

- ROIC including acquisitions, ten-year median: -201.5%

Chart: ROIC excluding acquisitions; fiscal year observations.

- FY2018: -23.9%

- FY2019: -303.6%

- FY2020: -207.9%

- FY2021: -228.7%

- FY2022: -151.5%

- FY2023: -194.8%

- FY2024: -279.4%

- FY2025: -243.9%

### economics: fail

- owner earnings cash conversion below threshold

- incremental invested capital return below threshold

- Cash conversion uses consolidated totals: No

- Owner earnings, five-year total: -$1.1B

- Net income, five-year total: -$1.1B

- Return on incremental invested capital: -316.7%

Chart: Owner earnings · five years; fiscal year observations.

- FY2021: -$171M

- FY2022: -$224M

- FY2023: -$255M

- FY2024: -$255M

- FY2025: -$213M

### management: fail

- Historical market-dollar context (not the management verdict): 2018 to 2025 (7 years)

- potential debt-funded buybacks (informational)

- buybacks unrelated to price (informational)

- ROIC first 3 years vs last 3 years: -207.9% vs -243.9%

- Per-share earnings: -1.89 to -2.73 (three-year endpoint medians)

- per-share value declined or ends nonpositive

- Management verdict uses per-share economic progress: Yes

- Ordinary dilution, 5-year annual growth: 14.9%

- Market cap gain: -$289M

- Cumulative retained earnings: -$1.3B

- Diluted shares, 5-year annual growth: 14.9%

- $1 test, starting fiscal year: FY2018

- $1 test, ending fiscal year: FY2025

- Per-share value change: -$0.84

- Per-share value, starting three-year median: -$1.89

- Per-share value, ending three-year median: -$2.73

- Buybacks concentrated in cheaper years (correlation): -0.40

- Average buyback yield: 0.0%

- Buyback history: 4 years

- Debt-funded buybacks: Yes

- ROIC, first three-year median: -207.9%

- ROIC, last three-year median: -243.9%

Chart: Earnings per share; fiscal year observations.

- FY2018: -$1.89

- FY2019: -$1.70

- FY2020: -$2.65

- FY2021: -$2.67

- FY2022: -$3.26

- FY2023: -$2.92

- FY2024: -$2.73

- FY2025: -$2.01

### accounting: pass

- Sloan accruals: -10.0%

- Restructuring years, last five: 1

- Earnings backed by cash: Yes

- Accounting red flags: 0

- Goodwill and intangibles / equity: 0.23×

Chart: Sloan accruals; fiscal year observations.

- FY2018: -8.2%

- FY2019: -5.0%

- FY2020: -12.2%

- FY2021: -9.6%

- FY2022: -7.9%

- FY2023: -8.9%

- FY2024: -9.3%

- FY2025: -10.0%

## Holders

- [Lee Ainslie](https://gigainvestors.com/mc): tracked 13F investor; follow the investor page for holding quarter and amounts.

## Price story

Down 92% since Dec 2023 · "Rocket lays off staff; Abivax capitalizes on immune drug data" (finance.yahoo.com, Jul 2025) · net income USD -223.1M

Story as of 2026-10-16T09:59:28.736Z; price observation 2026-10-15.

- 2025-07-17: Rocket Pharmaceuticals stock surges after FDA grants key designation ([investing.com](https://www.investing.com/news/stock-market-news/rocket-pharmaceuticals-stock-surges-after-fda-grants-key-designation-93CH-4139864))

- 2025-08-21: RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study ([finance.yahoo.com](https://finance.yahoo.com/news/rckt-stock-rises-fda-lifts-151300165.html))

- 2025-10-15: RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy ([finance.yahoo.com](https://finance.yahoo.com/news/rckt-stock-fda-accepts-resubmitted-153100740.html))

### Net income · FY2025

net income USD -223.1M; source https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm; observed 2026-02-26.

- FY2018: -$75M 

- FY2019: -$83M 

- FY2020: -$147M 

- FY2021: -$169M 

- FY2022: -$222M 

- FY2023: -$246M 

- FY2024: -$259M 

- FY2025: -$223M 

## Owner memo

Memo as of 2026-10-16T08:06:05.509Z.

### Where the cash goes

Paid dividends in 2 of 8 years; bought back USD 67000 of shares.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-26); Dividend observations: [[2018,0],[2019,0],[2020,5557000],[2021,0],[2022,172000],[2023,0],[2024,0],[2025,0]]. Zero only counted when supported by a complete cash-flow statement.

- Source: https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm (filed 2026-02-26); FY2025: cash repurchases 67000 USD.

### Are managers owners

Insiders own 3.2% of the company.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-05); RCKT.US SharesStats.PercentInsiders = 3.1809999999999996 percentage points; cache date 2026-10-05.

### What the price says

The price is 0.9 times net assets; cash earnings are negative.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-26); Closing price 2.36 USD; reporting-to-trading FX 1; FY2025 net assets per share 2.49470477828461; price multiple 0.9460037197759188. FY2025 cash earnings/share -1.9126240947368867. Closing-price date 2026-10-15.

## Monthly share-price history (USD per share)

- 2016-10: $7.00 per share

- 2016-11: $6.40 per share

- 2016-12: $6.10 per share

- 2017-01: $1.60 per share

- 2017-02: $1.60 per share

- 2017-03: $2.00 per share

- 2017-04: $2.00 per share

- 2017-05: $1.70 per share

- 2017-06: $1.90 per share

- 2017-07: $0.91 per share

- 2017-08: $1.02 per share

- 2017-09: $1.78 per share

- 2017-10: $2.52 per share

- 2017-11: $2.31 per share

- 2017-12: $2.61 per share

- 2018-01: $19.04 per share

- 2018-02: $16.98 per share

- 2018-03: $18.75 per share

- 2018-04: $17.24 per share

- 2018-05: $19.44 per share

- 2018-06: $19.63 per share

- 2018-07: $20.51 per share

- 2018-08: $23.85 per share

- 2018-09: $24.62 per share

- 2018-10: $15.84 per share

- 2018-11: $16.11 per share

- 2018-12: $14.82 per share

- 2019-01: $14.38 per share

- 2019-02: $17.41 per share

- 2019-03: $17.54 per share

- 2019-04: $18.56 per share

- 2019-05: $16.33 per share

- 2019-06: $15.00 per share

- 2019-07: $12.18 per share

- 2019-08: $10.85 per share

- 2019-09: $11.65 per share

- 2019-10: $14.54 per share

- 2019-11: $17.59 per share

- 2019-12: $22.76 per share

- 2020-01: $20.48 per share

- 2020-02: $19.49 per share

- 2020-03: $13.95 per share

- 2020-04: $14.80 per share

- 2020-05: $18.81 per share

- 2020-06: $20.93 per share

- 2020-07: $23.53 per share

- 2020-08: $25.57 per share

- 2020-09: $22.86 per share

- 2020-10: $27.94 per share

- 2020-11: $30.96 per share

- 2020-12: $54.84 per share

- 2021-01: $55.08 per share

- 2021-02: $55.58 per share

- 2021-03: $44.37 per share

- 2021-04: $45.84 per share

- 2021-05: $42.50 per share

- 2021-06: $44.29 per share

- 2021-07: $35.82 per share

- 2021-08: $34.21 per share

- 2021-09: $29.89 per share

- 2021-10: $29.71 per share

- 2021-11: $24.43 per share

- 2021-12: $21.83 per share

- 2022-01: $16.64 per share

- 2022-02: $17.81 per share

- 2022-03: $15.86 per share

- 2022-04: $10.28 per share

- 2022-05: $11.85 per share

- 2022-06: $13.76 per share

- 2022-07: $14.50 per share

- 2022-08: $15.41 per share

- 2022-09: $15.96 per share

- 2022-10: $18.66 per share

- 2022-11: $18.88 per share

- 2022-12: $19.57 per share

- 2023-01: $21.73 per share

- 2023-02: $19.21 per share

- 2023-03: $17.13 per share

- 2023-04: $17.92 per share

- 2023-05: $20.93 per share

- 2023-06: $19.87 per share

- 2023-07: $18.05 per share

- 2023-08: $15.65 per share

- 2023-09: $20.49 per share

- 2023-10: $18.10 per share

- 2023-11: $23.33 per share

- 2023-12: $29.97 per share

- 2024-01: $28.73 per share

- 2024-02: $29.30 per share

- 2024-03: $26.94 per share

- 2024-04: $21.52 per share

- 2024-05: $21.32 per share

- 2024-06: $21.53 per share

- 2024-07: $24.20 per share

- 2024-08: $18.85 per share

- 2024-09: $18.47 per share

- 2024-10: $16.65 per share

- 2024-11: $14.39 per share

- 2024-12: $12.57 per share

- 2025-01: $10.74 per share

- 2025-02: $9.45 per share

- 2025-03: $6.67 per share

- 2025-04: $7.63 per share

- 2025-05: $2.51 per share

- 2025-06: $2.45 per share

- 2025-07: $3.05 per share

- 2025-08: $3.28 per share

- 2025-09: $3.26 per share

- 2025-10: $3.77 per share

- 2025-11: $3.42 per share

- 2025-12: $3.51 per share

- 2026-01: $3.48 per share

- 2026-02: $5.01 per share

- 2026-03: $3.58 per share

- 2026-04: $3.48 per share

- 2026-05: $3.07 per share

- 2026-06: $3.42 per share

- 2026-07: $3.11 per share

- 2026-08: $3.72 per share

- 2026-09: $2.63 per share

- 2026-10: $2.36 per share

## Annual estimated value (USD per share)

Historical values use today's bond yield for every fiscal year

Historical values use today's FX rate into trading currency for every fiscal year

Historical values use current restated fundamentals and current commodity classification; they are not point-in-time estimates

## Sources

[Original 10-K filing](https://www.sec.gov/Archives/edgar/data/1281895/000119312526076551/rckt-20251231.htm); period 2025-12-31, filed 2026-02-26.

Estimates depend on assumptions and are not guarantees or investment advice. Underlying data remains subject to its source licenses; public reading does not grant bulk redistribution rights.